ABO2203 Injection

DRUG2 trials

Sponsors

Ruijin Hospital

Conditions

Autoimmune DiseasesB-cell Non-Hodgkin Lymphoma

Early Phase 1

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

RecruitingNCT06747156

Ruijin HospitalAutoimmune Diseases

Start: 2024-12-23End: 2028-12-01Target: 66Updated: 2026-03-24

Phase 1

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

RecruitingNCT07072169

Ruijin HospitalB-cell Non-Hodgkin Lymphoma

Start: 2025-05-26End: 2027-05-31Target: 56Updated: 2025-07-18

Related Papers

Abstract CT032: ABO2203, a messenger RNA encoding a CD3×CD19 T cell engager, for relapsed/refractory B cell non-Hodgkin lymphoma: Preliminary results from first-in-human study

Cancer Research2026-04-17